Related Experiment Videos
[Inhibition of platelet function by KB-2796]
N Yamamoto1, K Yokota, A Yamashita
1New Drug Research Laboratories, Kanebo Ltd., Osaka, Japan.
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
|November 1, 1991
Summary
KB-2796, a novel compound, demonstrates significant anti-platelet activity by inhibiting platelet aggregation and function. This research suggests its potential therapeutic role in managing thrombotic events.
Area of Science:
- Pharmacology
- Biochemistry
- Hematology
Context:
- Platelet aggregation plays a crucial role in thrombosis.
- Developing effective anti-platelet agents is vital for cardiovascular disease prevention.
- Understanding the mechanisms of platelet inhibition is key to drug development.
Purpose:
- To investigate the anti-platelet activity of KB-2796.
- To elucidate the mechanism of action of KB-2796 in inhibiting platelet function.
- To evaluate the efficacy of KB-2796 in animal models of thrombosis.
Summary:
- KB-2796 inhibited platelet function in guinea pig platelet-rich plasma, with IC50 values for [3H]5-HT release, collagen-induced, and ADP-induced aggregation at 940, 210, and 390 microM, respectively.
- Oral KB-2796 (10-100 mg/kg) dose-dependently inhibited collagen-induced thrombocytopenia and protected mice from collagen/epinephrine-induced death (ED50 = 9.5 mg/kg, p.o.).
- KB-2796 reduced platelet retention and inhibited ADP/ATP leakage from erythrocytes, suggesting erythrocyte stabilization as a primary mechanism.
Impact:
- KB-2796 exhibits potent anti-platelet properties.
- The compound's mechanism involves inhibiting ADP and ATP leakage from erythrocytes.
- KB-2796 shows promise as a therapeutic agent for thrombotic disorders.